The University of Texas MD Anderson Cancer Center IOTOX Symposium Treating Immune-Related Adverse Events Integrating Insights from Clinical, Translational and Basic Science 2024

The University of Texas MD Anderson Cancer Center IOTOX Symposium Treating Immune-Related Adverse Events Integrating Insights from Clinical, Translational and Basic Science 2024

$20.00 USD
$20.00 USD
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out
The University of Texas MD Anderson Cancer Center IOTOX Symposium Treating Immune-Related Adverse Events Integrating Insights from Clinical, Translational and Basic Science 2024

The University of Texas MD Anderson Cancer Center IOTOX Symposium Treating Immune-Related Adverse Events Integrating Insights from Clinical, Translational and Basic Science 2024

$20.00
$20.00
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out

  • Share positive thoughts and feedback from your customer.

    Author

  • Share positive thoughts and feedback from your customer.

    Author

  • Share positive thoughts and feedback from your customer.

    Author
    View full details

    The University of Texas MD Anderson Cancer Center IOTOX Symposium Treating Immune-Related Adverse Events Integrating Insights from Clinical, Translational and Basic Science 2024

     Include: 3 videos + 1 pdf, size: 8.4 GB

    Target Audience: allergy and immunology, internal medicine, and medical oncology, as well as pharmacists, physician associates, and trainees

    Information:

    Date & Location: Wednesday, November 6, 2024, 12:00 PM – Thursday, November 7, 2024, 4:00 PM, TMC3 Collaborative Building, Houston, TX
    Target Audience
    Specialties – Allergy and Immunology, Internal Medicine, Medical Oncology
    Professions – Nurse – APRN, Nurse – LVN, Nurse – RN, Other, Pharmacist, Physician (MD or DO), Physician Associate, Student or Trainee
    Overview

    The IOTOX Symposium is designed to bring a diverse range of stakeholders together to foster collaboration, share cutting-edge research findings, and discuss treatment advancements in the field of immunotherapy toxicities. The Symposium will provide a platform for attendees to engage in in-depth discussions and attend presentations that highlight new methodologies, emerging technologies, and innovative clinical management strategies. By facilitating network and knowledge exchange, the Symposium seeks to drive scientific progress and translate research into practical treatment options to improve patient outcomes.

    Call for Abstracts
    We invite faculty, trainees and staff to submit abstracts in the areas of clinical, translational, and basic science research. Submission deadline has been extended. To be considered for oral presentation, submit by Sunday, Sept. 29, 11:59pm.

    Objectives
    At the conclusion of this activity, learners will be able to:
    1. Construct the guideline recommendations for each toxicity.
    2. Identify location and use of national societies guidelines for IOTOX.
    3. Implement IOTOX guidelines that are vetted by both oncologists and internal medicine specialists.
    4. Identify patient treatment plans to evaluate difficult patient circumstances as it pertains to IOTOX.
    5. Employ treatment plans and IOTOX guidelines to all providers including Pharmacists, APPs, Nurses and Trainees.

     

    + Topics:

    Agenda.pdf
    November 6 Part 1.mp4
    November 6 Part 2.mp4
    November 7.mp4

     

    • Detail:
    Wednesday, November 6, 2024
    Registration and Check-In
    12:00PM – 1:00PM
    Session 1: Welcome and Keynote Address
    Welcome Remarks
    1:00PM – 1:05PM
    David J. Tweardy, MDOverview & Introduction of Keynote Speaker
    (NO CE Credit Awarded) 
    Keynote Address: Reverse Translational Approaches to Drive Clinical Breakthroughs in Cancer Immunotherapy
    1:05PM – 1:50PM
    Padmanee Sharma, MD, PhD
    Q&A Session
    1:50PM – 2:00PM
    Session 2: Bedside to Bench: Integrating Clinical Practice and Translational Research in Immune-Mediated Colitis

    Moderators: Adi Diab, MD; and Roza Nurieva, PhD

    Clinical Management and Current Limitations in Treatment
    2:00PM – 2:30PM
    Yinghong Wang, MD, PhD
    Clinical Trials and Translational Approaches to Solve Clinical Problems
    2:30PM – 3:00PM
    Michael Dougan, MD, PhD
    Interrogating the role of the IL-6/IL-23-Th17 axis in Immune-Mediated Colitis
    3:00PM – 3:30PM
    Adi Diab, MD
    Pre-Clinical Models for Investigation of Immune-Mediated Colitis
    3:30PM – 4:00PM
    Roza Nurieva, PhD
    Q&A Session
    4:00PM – 5:00PM
    Break and Networking
    5:00PM – 5:15PM
    Session 3: Poster Presentations and Welcome Reception
    Session 3: Poster Presentations and Welcome Reception
    5:15PM – 6:30PM(No CE Credit Awarded) 
    Thursday, November 7, 2024
    Session 4: Day 2 Welcome and Keynote Address
    Welcome Remarks
    8:00AM – 8:05AM
    Christopher R. Flowers, MD, FASCOOverview & Introduction of Keynote Speaker
    (NO CE Credit Awarded) 
    Keynote Address: Bridging Boundaries: National Efforts to Address Immunotherapy Toxicity
    8:05AM – 8:50AM
    Pauline Funchain, MD
    Q&A Session
    8:50AM – 9:00AM
    Session 5: Round Table Discussions – Relevance of Mouse Models for Clinical Management of irAEs

    Moderators: Adi Diab, MD; and Roza Nurieva, PhD

    Panelists for Mouse Studies
    9:05AM – 9:10AM
    Seyed Javad M. Moghaddam, MD
    Kristen Pauken, PhDPanelists for Mouse Studies:
    Kristen Pauken, PhD; and Seyed Moghaddam, MD 

    Panelists for Human Studies:
    Sumit Subudhi, MD; and Ala Abudayyeh, MD

    Topics to be Discussed:
    • What is Heavily Conserved and Readily Modeled
    • How to Translate These Findings Clinically

    Q&A Session

    Panelists for Human Studies
    9:10AM – 9:20AM
    Sumit K Subudhi, MD, PhD
    Ala Abudayyeh, MD
    Break
    10:30AM – 10:40AM
    Session 6: Clinical Challenges and Research Directions in irAEs I

    Moderators: Bilal A. Siddiqui, MD; and Sebastian T. Wurster MD

    Dermatologic irAEs
    10:40AM – 11:00AM
    Noah I Hornick, MD, PhD, FAAD
    Sebastian T Wurster, MD (Moderator)
    Q&A Session
    11:00AM – 11:10AM
    Endocrine irAEs
    11:10AM – 11:30AM
    Nupur Kikani, MD
    Q&A Session
    11:30AM – 11:40AM
    Rheumatologic irAEs
    11:40AM – 12:00PM
    Alexa Meara, MD
    Q&A Session
    12:00PM – 12:10PM
    Lunch
    12:10PM – 1:10PM
    Session 7: Clinical Challenges and Research Directions in irAEs II

    Moderators: Yinghong (Mimi) Wang, MD, PhD; and Ashley Aaroe, MD

    Neurologic irAEs
    1:10PM – 1:30PM
    Bianca Santomasso, MD, PhD
    Q&A Session
    1:30PM – 1:40PM
    Cardiac irAEs
    1:40PM – 2:00PM
    Nicolas Palaskas, MD
    Q&A Session
    2:00PM – 2:10PM
    Pulmonary irAEs
    2:10PM – 2:30PM
    Ajay Sheshadri, MD
    Q&A Session
    2:30PM – 2:40PM
    Session 8: Oral Abstract Presentations

    Moderators: Arielle Raugh, PhD; and Synat Keam, PhD

    Reported Immunotherapy Toxicities on FDA Registration Trials for Solid Tumors – Is There More Than Meets the Eye?
    2:40PM – 2:50PM
    Matthew J Hadfield, DO
    Q&A Session
    2:50PM – 2:55PM
    Mechanistic Insights on Immune Checkpoint Inhibitor-Induced Recurrent Inflammatory Arthritis
    2:55PM – 3:05PM
    Synat Keam Sr., PhD
    Q&A Session
    3:05PM – 3:10PM
    Integrating Genetic and Radiographic Markers to Predict Immune Checkpoint Inhibitor Pneumonitis Risk in Non-Small Cell Lung Cancer
    3:10PM – 3:20PM
    Felipe Soto Lanza, MBBS,MD
    Q&A Session
    3:20PM – 3:25PM
    Modeling Immune Checkpoint Inhibitor-Induced Colitis: Mechanistic Insights and Therapeutic Targets
    3:25PM – 3:35PM
    Naimah Turner, MS
    Q&A Session
    3:35PM – 3:40PM
    Closing Remarks
    3:40PM – 3:45PM